<DOC>
	<DOC>NCT00892931</DOC>
	<brief_summary>The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme</brief_summary>
	<brief_title>Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Have histologically proven malignant Glioblastoma Multiforme in first or second relapse Have failed prior Fractionated External Beam Cranial Irradiation or IMRT Be at least 18 years old and with a life expectancy ≥ 8 weeks or ≥ 4 weeks if failed prior Avastin therapy Have a Karnofsky performance status of ≥ 60 Have adequate bone marrow function, liver function, and renal function before starting therapy Have had more than two relapses Have had radiosurgery Have a cardiac ejection fraction &lt; 50% by MUGA or ECHO Have TroponinI elevated above the normal range Have an increasing steroid requirement Have MRI evidence at baseline of enlarging or clinically significant intratumor hemorrhage Have active stroke and/or transient ischemic attack not optimally managed Have active cardiovascular disease (e.g. suboptimally managed angina, impending myocardial infarction, or uncontrolled hypertension) Be pregnant or breast feeding Have had prior hypersensitivity reaction to Cremophor EL Be HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Brain Neoplasms</keyword>
	<keyword>Recurrence</keyword>
</DOC>